Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCH vs EC-TH in HER2+ Breast Cancer
NCT03140553Phase 2Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2016
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, carboplatin, trastuzumab in HER2-positive breast cancer, sponsored by Guangdong Provincial People's Hospital. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03140553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140553.